Aptargroup Inc
ATR
ISIN null / Valor 68947
Aptargroup Inc
UMushroom community rating:
About company
Aptargroup Inc., headquartered in Crystal Lake, Illinois, operates as a prominent provider in the realm of drug delivery systems, consumer product dispensing, and active material science solutions. With a workforce of over 13,000 employees spread across 20 countries, the company caters to a diverse range of industries including pharmaceuticals, beauty, food and beverage, personal care, and home care. Aptargroup's business model is centered around innovation and adaptability, ensuring that both the company and its clients' products remain relevant in the face of changing market demands. By offering specialized services and products in drug delivery and consumer product dispensing, Aptargroup plays a crucial role in enhancing the functionality and user experience of a wide array of consumer goods and pharmaceuticals.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (13.11.2025):
AptarGroup Inc’s third quarter 2025 results showed solid financial performance with reported sales rising 6% to $961 million and net income increasing 28% to $128 million. The company delivered an EPS boost to $1.92 and maintained modest increases in adjusted earnings and EBITDA, driven by robust growth in its Pharma segment—particularly in injectables—and a disciplined approach to capital deployment and operational execution.
Sales Performance
Reported sales increased 6% year-over-year, with core sales up 1%. The Pharma division notably contributed with a 6% sales increase and a robust 18% uplift in its injectables segment, reflecting strong demand for GLP-1 components.
Earnings & Profitability
Net income jumped 28% to $128 million and reported EPS rose from $1.48 to $1.92. Adjusted EPS increased moderately to $1.62 while adjusted EBITDA grew 7% to $223 million, helping to enhance the EBITDA margin to 23.2%.
Segment Insights
The Pharma segment led growth with higher sales volumes, while Aptar Beauty benefited from favorable currency effects and acquisitions. In contrast, Aptar Closures experienced mixed results due to lower tooling sales and pass-through effects from resin pricing.
Outlook & Shareholder Returns
The company anticipates a positive Q4 2025 with adjusted EPS guidance between $1.20 and $1.28 and expects continued growth driven by a strong Pharma pipeline. Additionally, Aptar returned $70 million to shareholders during the quarter through share repurchases and dividends.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
8055 M
Market cap (USD)
198,018
Daily traded volume (Shares)
157.49 / 155.11
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
